Skip to main content
Journal cover image

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)

Publication ,  Conference
Gourley, C; Miller, A; Paul, J; Carty, K; Rodgers, W; Millan, D; Connolly, K; Gabra, H; Banerjee, S; Coleman, R; Moore, KN; Secord, AA ...
Published in: International Journal of Gynecological Cancer
November 2025

Duke Scholars

Published In

International Journal of Gynecological Cancer

DOI

ISSN

1048-891X

Publication Date

November 2025

Volume

35

Issue

11

Start / End Page

102736 / 102736

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gourley, C., Miller, A., Paul, J., Carty, K., Rodgers, W., Millan, D., … Gershenson, D. (2025). FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). In International Journal of Gynecological Cancer (Vol. 35, pp. 102736–102736). Elsevier BV. https://doi.org/10.1016/j.ijgc.2025.102736
Gourley, Charlie, Austin Miller, Jim Paul, Karen Carty, William Rodgers, David Millan, Kathryn Connolly, et al. “FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC).” In International Journal of Gynecological Cancer, 35:102736–102736. Elsevier BV, 2025. https://doi.org/10.1016/j.ijgc.2025.102736.
Gourley C, Miller A, Paul J, Carty K, Rodgers W, Millan D, et al. FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). In: International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102736–102736.
Gourley, Charlie, et al. “FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC).” International Journal of Gynecological Cancer, vol. 35, no. 11, Elsevier BV, 2025, pp. 102736–102736. Crossref, doi:10.1016/j.ijgc.2025.102736.
Gourley C, Miller A, Paul J, Carty K, Rodgers W, Millan D, Connolly K, Gabra H, Banerjee S, Coleman R, Moore KN, Secord AA, O’Malley D, Dorigo O, Gaillard S, Waggoner S, Wolfson A, Edelson M, Hagemann A, Guntupalli S, Huang H, Wenzel L, Gershenson D. FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC). International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102736–102736.
Journal cover image

Published In

International Journal of Gynecological Cancer

DOI

ISSN

1048-891X

Publication Date

November 2025

Volume

35

Issue

11

Start / End Page

102736 / 102736

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis